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Abstract: The last few years have featured an increasing interest in the study of the human microbiome
and its correlations with health status. Indeed, technological advances have allowed the study
of microbial communities to reach a previously unthinkable sensitivity, showing the presence of
microbes also in environments usually considered as sterile. In this scenario, microbial communities
have been described in the amniotic fluid, the umbilical blood cord, and the placenta, denying
a dogma of reproductive medicine that considers the uterus like a sterile womb. This prenatal
microbiome may play a role not only in fetal development but also in the predisposition to diseases
that may develop later in life, and also in adulthood. Thus, the aim of this review is to report the
current knowledge regarding the prenatal microbiome composition, its association with pathological
processes, and the future perspectives regarding its manipulation for healthy status promotion
and maintenance.
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1. Introduction
The human microbiome has emerged as an important factor required for human health status
acquisition and maintenance [1,2]. Indeed, several reports have demonstrated that microbial alterations
(or dysbiosis) can be found in an increasing number of human diseases and that their entities may
be associated with the severity of the phenotype or with the sensitivity to specific therapies [1–8].
Thus, even if it has not been well established yet whether the microbiome alterations are the cause or
the consequence of diseases, their study is intriguing since it opens the way to the identification of
novel disease-specific biomarkers, or to the development of targeted therapies aiming to manipulate
the microbiome in the attempt to restore a healthy status [9–17]. Next generation sequencing-based
approaches have assessed their reliability in metagenomic studies escalating the possibility to describe
microbial communities in detailand obtain both qualitative and quantitative information [1,2,18,19].
As a consequence, it is now widely accepted that microbes live on the surface and inside our body,
colonizing also body niches that were traditionally considered as “sterile.” This applies also to the
fetal environment [20–22]. Indeed, technological advances in metagenomics have denied a central
dogma of reproductive medicine stating that the fetus stays in a sterile niche (i.e., the uterus) and is
colonized by bacteria only at birth [23]. The prenatal microbiome seems not only to have a role in fetal
development but may also influence the subsequent adult health status [24–26]. Thus, understanding
fetal microbiome origins and the factors able to influence its composition is important to clarify diseases
pathogenesis and identify also maternal factors that, acting at a prenatal age, may predispose the
development of diseases including later in adulthood [24–26]. The aim of this review is to describe the
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knowledge on prenatal microbiome, its association to specific diseases, and its possible manipulation
to promote a healthy status.
2. The Prenatal Microbiome
For about a century, it has been assumed that the fetus is sterile and that microbes colonize
the newborn immediately during birth, withthe delivery mode being an important modifying
factor [23,27,28]. The placenta, in particular, has been considered for years like a barrier able to
prevent fetal contamination by maternal toxins and microbes, thus preserving fetal sterility and
ensuring proper fetal development [26,29,30]. In contrast with these beliefs, recent studies have shown
that microbes colonize the amniotic fluid, the umbilical blood cord, and the placenta, suggesting that
a maternal microbial colonization of the fetus mayalready begin in utero [20–26,30]. In particular,
the presence of an established microbiota in healthy and term infants, in absence of any infection or
inflammation, supports the hypothesis that not only microbes colonize the fetus before birth, but that
they may also play a role into the physiological development of the fetus.
In support of this hypothesis, microbial communities have been found also in the meconium
of newborns [31–42]. Jiménez et al. first demonstrated the non-sterility of infant meconium [31].
These authors were also able to showthe presence of a maternal–fetalin utero transmission of gut
microbiota; they used a mouse model to verify that a specific Enterococcus faecium strain, maternally
administer viaoral instillation, was present in the gut of the pups delivered 1 day prematurely
bycesarean section [31]. Subsequently, several reports using different molecular strategies have
described microbial meconium communities, also highlighting interesting differences between term
and preterm infants [32–34]. In particular, Mshvildadze et al. characterized the meconium microbiome
of 23 neonates, revealing an association between a reduced microbial diversityand prematurity [32].
In a prospective longitudinal study, Madanet al. found thatthe predominant bacterial genera in the
meconium specimens obtained from six preterm neonates were Lactobacillus, Staphylococcus, and
Enterobacteriaceae [33]. Ardissone et al. analyzed the meconium collected from 52 infants with
gestational ages ranging from 23 to 41 weeks and found that the gestational age was correlated
with low bacterial diversity and microbial colonization [34]. In addition, this study revealed similar
microbial features between the meconium and the amniotic fluid, thus supporting the hypothesis of an
intrauterine origin of the meconium microbiota, as a consequence of the amniotic fluid swallowing
by the fetus during the last trimester of pregnancy [34]. According to these findings, Collado et al.
analyzed the microbiome of multiple samples from mother–offspring pairs, including the placenta, the
meconium, and the amniotic fluid, and highlighted the presence of common microbial features [35]. The
meconium microbiota has features of a low biodiversity and a high inter-individual variability [36,37].
Bäckhedet al. found that in the meconium microbiota, the genera Escherichia-Shigella and Enterococcus
were more abundant and Bacteroides and Bifidobacterium less abundant with respect to infants fecal
microbiota [38]. Tapiainen et al. carried out a large population-based study, recruiting 218 consecutively
birth newborns, to assess the role of bacterial exposures before birth on the meconium microbiome
composition [39]. They found that maternal factors occurring during pregnancy affect the meconium
microbiome composition supporting the hypothesis of the in utero transfer of microbes [39].
Other studies have investigated the potential impact of the delivery mode on the meconium
microbiome composition [40–42]. By analyzing the 16S rRNA profiles of rectal swabs obtained at birth
by full-term infants, Dominguez-Bello et al. found that meconium microbiota composition is influenced
by delivery mode [40]. In particular, they highlighted that in cesarean-delivered infants, there was
a prevalence of Staphylococci with respect to the vaginally-delivered babies, whose microbiome was
featured by the presence of genera like Lactobacillus and Prevotella, resembling the skin microbiome,
and the vaginal microbiome, respectively [40]. Other studies performed on independent cohorts of
full-term infants also found that the meconium microbiota of vaginally-delivered infants is dominated
by lactic acid or enteric bacteria [41,42].
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Even if the origin of meconium microbiota has been not yet clearly established, these data suggest
that the establishment of intestinal microbiota is initiated in the prenatal gut. Indeed, as stated above,
recent evidence has overcome the traditional view of the in utero environment as being a sterile room
(Figure 1A) [20–22].
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Figure 1. Prenatal microbiome colonization. (A) For years the uterus has been considered as a
sterile womb in which the fetus is protected by the placenta from microbial colonization. (B) Recent
studies have questioned this hypothesis showing that microbial colonization may already begin in
utero; these microbes may reach the fetus from the maternal oral cavity/gut through the bloodstream
(hematogenous route) and from the vagina (ascendant route).
In particular, the presence of bacteria in the placenta of preterm newborns or in case of intrauterine
infections is not surprising. However, bacteria have also been found in the placenta of at term
pregnancy, without any sign of infection, and also after cesarean section under sterile conditions [43].
Aagaard et al. used 16S rRNA sequencing to analyze the placenta-related microbial communities of
320 women and revealed the presence of a low-abundant, but metabolically rich microbiota, featured by
the presence of bacteria belonging to the phyla Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes,
and Fusobacteria [44]. Bacterial communities have been found also in the amniotic fluid, even
without amniotic sac ruptures [45]. Other studies have focused their attention on the umbilical cord
blood: Jiménez et al. analyzed the bacterial communities of healthy, full-term newborns after elective
cesarean delivery and highlighted the presence of commensal bacteria, like Enterococcus, Streptococcus,
Staphylococcus, and Propionibacterium [31].
All these data support the hypothesis of a prenatal origin of human microbiome. However, the
origin of this fetal microbiome is still unknown (Figure 1B). The currently accepted theory is that
fetal microbial bacteria may originate both from the vaginathrough ascendant colonization [46–50],
and from the maternal oral cavity/gut through the bloodstream (hematogenous route) [31,44,51–55].
Additional studies are required to better clarify these issues.
3. C rrelation betwe n Fetal Microbiome and N wborn’s Health
The human gut is the organ with the highest density of microbial communities [1–4,6–8,56]. These
communities are involved in several functions required for human host healthy status [1–4,6–8,56].
Thus, t e initial microbial colo ization of uman gut is a critical step ble to influence the host health
and diseases risk through th establishment of a number of microbes–human inter ctions [21–26].
Maternal and early life environmental factors can both influence the gut microbiota development
and composition and, s a consequence, may increase the risk of several chronic and metabolic
diseases later in life [21–26]. Indeed, maternal micr bial communities, including prenatal gut, vaginal,
oral, and skin microbiomes, undergo pronounced changes during preg ancy that may affect healthy
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status maintenance and contribute to the development of common diseases [20]. To date, a microbial
dysbiosis of the infant gut has been associated to the development of asthma, allergic diseases, and
obesity [21–26]. Thus, considering that it has been established that the fetus does not stay in a sterile
environment and that the microbial colonization begins in utero, factors that are able to influence this
first colonization may impact on newborn’s future health.
In particular, it is now clear that the fetal immune system is not inactive but, being exposed
through the mother to environmental stimuli, interacts with the maternal immune system [57,58].
Indeed, several maternal factors, including hormones, cytokines, and the microbiome, can modify the
intrauterine environment, thus impacting fetal immune system development [57,59,60]. The toll-like
receptors (TLRs) are a class of receptors present on the surface of different cells (macrophages, mast
cells, and dendritic cells) involved in the innate immunity. Since different types of TLRs are able
to recognize distinct bacteria driving the development of a potential inflammatory response, it has
been proposed that intrauterine bacteria may influence the fetal immune system development though
the TLRs [61,62]. Another possible mechanism of bacterial influence on the fetal immune system
development may be represented by the production of short chain fatty acids (SCFAs) that are able to
induce T-cells activation and modulate interleukin -10 production [63,64]. Finally, mucosa-associated
invariant T cells (MAIT) have also been identifiedin the fetus starting from the second trimester of
pregnancy [65,66]. These cells are able to recognize microbial metabolites and, consequently, to produce
inflammatory cytokines supporting the hypothesis of in utero activity [66,67].
Considering all the above, it is easy to understand that all the factors influencing maternal health,
including maternal habits, during pregnancy and the partum can influence the microbial colonization
of the fetus. Chu et al. evaluated the effect of maternal diet on meconium microbiome composition [68].
In this study, 81 mother-infants couples were analyzed to highlight microbial alterations related to
maternal diet during pregnancy. Interestingly, meconium microbial communities were significantly
different in high fat respect to balanced diet exposed infants, Bacteroides being significantly reduced
in high-fat exposed infants [68]. Another study by Lundgren et al. aimed to verify the relationship
between maternal diet during pregnancy and the stool microbiome evaluated 6 weeks after birth [69].
In total, 145 infant/mother couples were analyzed showing that several maternal dietary factors
during pregnancy influenced infants’ stool microbiomes and that these alterations are also related to
the delivery mode [69]. Collado et al. found that infants’microbiomes are influenced by the mother
beingoverweight during pregnancy [70]. In particular, this study highlighted that in the presence of
an excessive maternal weight gain during pregnancy, newborns have lower amounts of the genera
Bacteroides and Prevotella with respect to those born from mothers with regular weight gain [70]. Hu et al.
studied the correlation between maternal gestational and pre-gestational type 2 diabetes and the
meconium microbiome composition [36]. Interestingly, they found that Bacteroides, Parabacteroides, and
Lachnospiraceae were more abundant in the meconium of infants in the presence of maternal diabetes
and that these alterations were higher in the case of pre-gestational diabetes [36]. Gosalbes et al.
verified the effects of maternal atopic diseases on the meconium microbiome [41]. They found that
maternal eczema is able to modify the meconium bacterial composition, being associated with a lower
bacterial diversity and richness and to an increased abundance of the Enterobacteriaceae family, while
maternal asthma or rhinitis seem to not induce microbial changes [41]. Finally, Mshvildadze et al.
showed that a lower bacterial diversity was present in the meconium of infants whose mothers received
intra-partum antibiotics [32]. A recent interesting study by Lammert et al. investigated the role of
the prenatal microbiome on the development of behavioral alterations [71]. Using a mouse model
of autism, they were able to assess that prenatal microbiota transplantation is able to modulate the
maternal immune system and transfer the susceptibility to neurodevelopmental disorders [71].
These studies support the hypothesis that environmental factors during pregnancy can modify
maternal microbiome and may affect the fetal environment. However, the effects of this in utero
colonization on newborns future health are not yet clearly understood and further studies on large
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cohorts of subjects are required to investigate how environmental stimuli can impact maternal
microbiome during pregnancy and the long-term effects of these perturbations on infants’ health.
4. Manipulation of Prenatal Microbiome for Healthy Status Maintenance
As discussed in the previous sections, recent studies have shown that microbial colonization
begins already before birth and that both maternal and environmental factors may play a role in this
microbial early colonization. Even if the origin of the prenatal microbiome is still poorly understood
and its correlation with newborns health and disease status also needs to be further investigated,
if confirmed by future studies, it may become an actionable target to promote infant health by inducing
the colonization of beneficial bacteria and avoiding those considered harmful.
Indeed, unlike the human genome, the microbiome can be easily modified, and its evaluation
may be useful not only to stratify individuals based on a specific disease risk, but also to monitor
them overtime [72]. In addition, while inter-individual differences in the response to specific therapies
are well known, few data are available regarding the role of microbiomes in these phenomena, even
if it has been established that the gut microbiota is involved in the metabolic transformation of
several therapeutic compounds [72]. Thus, a better understanding of these processes may drive
personalized medicine by supporting the choice of the most proper treatment and minimizing the
onset of side effects.
Considering all the above, there is a lot of enthusiasm in this field since microbiome gives the
opportunity to have a non-invasive biomarker that can not only be used for diagnostic purposes,
but is emerging as an easily actionable target for therapeutic interventions. Antibiotics, probiotics,
and prebiotics administration may be easily used to induce specific microbiome modifications [73–76].
In addition, enteral nutrition and microbiome transplantation have also shown their efficacy in some
specific conditions [77–79].
The more our knowledge on human microbiome and its role in disease pathogenesis increases,
the more the possibility to treat specific conditions (or at least to ameliorate their clinical outcome) by
microbiome manipulation becomes intriguing. This also applies to the prenatal microbiome: since
it is influenced by maternal habits during pregnancy, it is easy to imagine possible interventions
(for example on maternal diet) that are able to drive fetal microbial colonization. However, as in
other fields, a lot of limitations need to be assessed before microbiome manipulation can be genuinely
helpful in routine clinical assessments. Microbial inter-individual variability, technical challenges,
and potential pitfalls related to samples collection, analysis, and interpretation have to be taken
into account.
5. Conclusions
As reviewed above, in the last 10 years, the sterile womb paradigm has been changed to the in
utero colonization hypothesis. Indeed, microbial communities have been identified in the meconium,
the amniotic fluid, the umbilical blood cord, and the placenta in at term pregnancy and in absence of
infections [21,26].
To date, several reports have attempted to study the prenatal microbiome in order to clarify
its origins and functions, and consequently highlight a possible role in predisposing to diseases
development also later during life and adulthood [24–26]. Interesting associations have emerged and
these may be the bases for the possible use of the prenatal microbiome as a biomarker and also as a
potentially actionable target to be manipulated for personalized treatments aimed to reduce the risk
for specific diseases.
Of course, caution is required regarding the correct interpretation of these data. As recently stated
by Perez-Munoz et al. concerns exist regarding the detection limits of the used techniques (PCR and
next generation sequencing-based approaches do not have high enough sensitivity to study low-rich
bacterial communities), and with the high risk for environmental contaminations combined with
the lack of proper controls [30]. In addition, the currently used next generation sequencing-based
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technologies cannot discriminate between live, viable, and active versus dead, unviable, and inactive
bacteria. All these issues need to be taken into account when considering the prenatal microbiome
and its influence on future health. Maybe further studies combining traditional culture-based assays
and more extensive microbial communities studies (i.e., metabolomics, metatranscriptomics, and
metagenomics) may provide a more comprehensive view of the prenatal microbiome and its role.
Once these points are clarified and clearly assessed, novel perspectives for personalized and predictive
medicine may be available based on the knowledge of the prenatal microbiome.
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